Investors inquire whether Jinjia has a pod system e-cigarette product with a large capacity. If so, what are the market prospects for it?
On September 4th, Jinjia responded by stating that their subsidiary company has a variety of e-cigarette products with interchangeable cartridges. Product preferences vary among different regions and customer groups, and different countries also have unique policies regarding e-cigarettes. According to the 2022 World Tobacco Report, the global sales of e-cigarettes reached $23.65 billion, with a year-on-year growth of 20.0%. It is projected that the industry will continue to experience a growth trend in the future.
In addition, some investors have raised a question regarding how the company continues to produce and sell its existing Foogo disposable e-cigarette overseas, given that it does not possess an e-cigarette license domestically.
Jinjia Holdings responded by stating that its subsidiary, Shenzhen Galaxylink Technology, provides ODM/OEM and supply chain services for the export products of its customers, particularly in the field of new tobacco products. Meanwhile, Hang Tang International Management (Hong Kong) is primarily responsible for the import and export trade and marketing of tobacco and related products. In addition, Jinjia's new tobacco production in Indonesia has commenced trial production, and the second half of the year will focus on increasing production capacity and improving yield rates.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
